News

History says you should avoid HIMS stock right now

The weight-loss opportunity now comes with a margin tradeoff

Investing.com -- JPMorgan revealed Friday that it has started coverage of Hims & Hers Health at Neutral, setting a December 2027 price target of $32 as it weighs the direct-to-consumer health platform's rapid growth against execution risks in its shift to branded weight-loss drugs.

Pump.fun launches Custom Pairs, letting creators launch tokens against stocks, crypto, metals, and more while earning fees in the paired asset.

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.

HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.

HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.

The FDA reported more than 1,700 adverse events involving compounded Semaglutide and Tirzepatide

Hims & Hers Health, Inc. (NYSE:HIMS) has entered Australia, marking its first expansion into the Asia-Pacific market. The move follows its acquisition of Australian digital-health platform Eucalyptus, which includes men’s health brand Pilot and women’s health brand Juniper. Hims is initially rolling out weight-loss and men’s health treatments, with plans to introduce women’s health services […]

Hims & Hers Health stock has surged over the last three years, yet recent share price setbacks and a mixed valuation score leave investors weighing how much of the story is already reflected in the current price. The stock is up about 3.2x over the past three years. That puts extra focus on whether that strong run can be supported by future business performance. Plans to expand into experimental peptide therapies may support higher long term growth expectations. At the same time, regulatory...

Earlier this week, Hims & Hers Health reported quarterly revenue of US$753.2 million, up 38.2% year on year, added 307,000 customers to reach 2.89 million, and raised both next-quarter revenue guidance and full-year EBITDA guidance above analyst expectations. Alongside these financial updates, new survey findings on Gen Z sexual health attitudes and ongoing regulatory and legal scrutiny of Hims & Hers’ privacy and billing practices highlight both expanding demand for its services and...

On August 18, 2026, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum told CNBC that a Federal Trade Commission lawsuit over the company’s data-sharing and subscription practices “misunderstands how the company works.” He defended the company’s compounded GLP-1 drug sales as having helped lower prices for weight-loss treatments. Why This Matters Hims & Hers […]

On August 21, 2026, Bloomberg reported that Hims & Hers Health, Inc. (NYSE:HIMS) was enrolled in Visa Inc. (NYSE:V)’s Acquirer Monitoring Program after customer credit card disputes in its weight-loss subscription business exceeded acceptable levels in July. Each dispute carries an $8 surcharge, resulting in a bill of nearly $75,000 due in September, and Hims […]

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Hims & Hers Health (NYSE:HIMS) and its peers.

Hims & Hers Health is shifting its core weight-loss business from compounded GLP-1 drug sales to branded versions of the medications.

Check out the companies making headlines yesterday:

Hims faces an estimated $75,000 surcharge and must lower its dispute rate below 1.5%.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 9.2% in the afternoon session after Bloomberg reported that Visa enrolled the telehealth company in its Acquirer Monitoring Program following a surge in customer credit card disputes in its weight-loss subscription business.

Visa placed Hims & Hers Health into its Acquirer Monitoring Program after a billing dispute spike, adding penalty costs amid an FTC lawsuit and margin contraction.

TDOC's BetterHelp faces a capacity crunch as insurance demand surges, putting therapist recruitment and credentialing at the center.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Hims & Hers Health (HIMS) stock is back in focus after the Federal Trade Commission and state regulators filed a civil enforcement action, followed by a consumer class action targeting the company’s telehealth privacy and subscription practices. See our latest analysis for Hims & Hers Health. The latest 1-day share price return of 6.03% and 7-day return of 20.00% put Hims & Hers Health back in sharp focus. However, the 1-year total shareholder return is down 24.21%, while the 3-year total...

Hims & Hers Health (HIMS) was placed on notice by Visa for excessive customer complaints in its weig

Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 2% on Tuesday even after the telehealth company posted second-quarter revenue of $753.2 million, up 38% and above the $699 million analysts expected. The firm raised its full-year revenue outlook. Novo Nordisk A/S (NYSE:NVO) suffered a similar fate a week earlier, with shares dropping about 6% […]

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

This filing notes that shares were withheld automatically to cover tax obligations from quarterly RSU vesting.

This tax-related withholding was tied to quarterly RSU vesting, not discretionary selling.